Initial and Repeated Point Prevalence Surveys to Inform SARS-CoV-2 Infection Prevention in 26 Skilled Nursing Facilities - Detroit, Michigan, March-May 2020 by Sanchez, Guillermo V. et al.
Wayne State University 
Department of Pharmacy Practice Eugene Applebaum College of Pharmacy and Health Sciences 
7-1-2020 
Initial and Repeated Point Prevalence Surveys to Inform SARS-
CoV-2 Infection Prevention in 26 Skilled Nursing Facilities - 
Detroit, Michigan, March-May 2020 
Guillermo V. Sanchez 
Centers for Disease Control and Prevention 
Caitlin Bierdon 
Centers for Disease Control and Prevention 
Lauren R. Fink 
Detroit Health Department 
Kelly M. Hatfield 
Centers for Disease Control and Prevention 
Jordan Micah F. Polistico 
Detroit Medical Center 
See next page for additional authors 
F llow this and additional works at: https://digitalcommons.wayne.edu/pharm_practice 
 Part of the Occupational Health and Industrial Hygiene Commons, Pharmacy and Pharmaceutical 
Sciences Commons, Respiratory Tract Diseases Commons, and the Virus Diseases Commons 
Recommended Citation 
Sanchez, Guillermo V.; Bierdon, Caitlin; Fink, Lauren R.; Hatfield, Kelly M.; Polistico, Jordan Micah F.; 
Meyers, Monica P.; Noe, Rebecca S.; Copen, Casey E.; Lyons, Amanda K.; Gonzalez, Gonzalo; Kiama, Keith; 
Lebednick, Mark; Caander, Bonnie K.; Agbonze, Amen; Surma, Aimee R.; Sandhu, Avnish; Mika, Valerie H.; 
Prentiss, Tyler; Zervos, John; Dalal, Donia A.; Vasquez, Amber M.; Reddy, Sujan C.; Jernigan, John; Kilgore, 
Paul E.; Zervos, Marcus J.; Chopra, Teena; Bezold, Carla P.; and Rehman, Najibah K., "Initial and Repeated 
Point Prevalence Surveys to Inform SARS-CoV-2 Infection Prevention in 26 Skilled Nursing Facilities - 
Detroit, Michigan, March-May 2020" (2020). Department of Pharmacy Practice. 14. 
https://digitalcommons.wayne.edu/pharm_practice/14 
This Article is brought to you for free and open access by the Eugene Applebaum College of Pharmacy and Health 
Sciences at DigitalCommons@WayneState. It has been accepted for inclusion in Department of Pharmacy Practice 
by an authorized administrator of DigitalCommons@WayneState. 
Authors 
Guillermo V. Sanchez, Caitlin Bierdon, Lauren R. Fink, Kelly M. Hatfield, Jordan Micah F. Polistico, Monica 
P. Meyers, Rebecca S. Noe, Casey E. Copen, Amanda K. Lyons, Gonzalo Gonzalez, Keith Kiama, Mark 
Lebednick, Bonnie K. Caander, Amen Agbonze, Aimee R. Surma, Avnish Sandhu, Valerie H. Mika, Tyler 
Prentiss, John Zervos, Donia A. Dalal, Amber M. Vasquez, Sujan C. Reddy, John Jernigan, Paul E. Kilgore, 
Marcus J. Zervos, Teena Chopra, Carla P. Bezold, and Najibah K. Rehman 
This article is available at DigitalCommons@WayneState: https://digitalcommons.wayne.edu/pharm_practice/14 
Morbidity and Mortality Weekly Report
Early Release / Vol. 69 July 1, 2020
Initial and Repeated Point Prevalence Surveys to Inform SARS-CoV-2 
Infection Prevention in 26 Skilled Nursing Facilities — Detroit, Michigan, 
March–May 2020
Guillermo V. Sanchez, MSHS, MPH1; Caitlin Biedron, MD1; Lauren R. Fink, MPH2; Kelly M. Hatfield, MSPH1; Jordan Micah F. Polistico, MD3,4; 
Monica P. Meyer, MS, MPH3,4; Rebecca S. Noe, MN, MPH1; Casey E. Copen, PhD1; Amanda K. Lyons, MS1; Gonzalo Gonzalez, DNP2; 
Keith Kiama2; Mark Lebednick2; Bonnie K. Czander2; Amen Agbonze2; Aimee R. Surma, MS2; Avnish Sandhu, DO3,4; Valerie H. Mika, MS4; 
Tyler Prentiss, MA5; John Zervos, JD5; Donia A. Dalal2; Amber M. Vasquez, MD1; Sujan C. Reddy, MD1; John Jernigan, MD1; Paul E. Kilgore, MD4; 
Marcus J. Zervos, MD4,5; Teena Chopra, MD3,4; Carla P. Bezold, ScD2; Najibah K. Rehman, MD2
Skilled nursing facilities (SNFs) are focal points of the 
coronavirus disease 2019 (COVID-19) pandemic, and asymp-
tomatic infections with SARS-CoV-2, the virus that causes 
COVID-19, among SNF residents and health care personnel 
have been described (1–3). Repeated point prevalence sur-
veys (serial testing of all residents and health care personnel 
at a health care facility irrespective of symptoms) have been 
used to identify asymptomatic infections and have reduced 
SARS-CoV-2 transmission during SNF outbreaks (1,3). 
During March 2020, the Detroit Health Department and area 
hospitals detected a sharp increase in COVID-19 diagnoses, 
hospitalizations, and associated deaths among SNF residents. 
The Detroit Health Department collaborated with local 
government, academic, and health care system partners and a 
CDC field team to rapidly expand SARS-CoV-2 testing and 
implement infection prevention and control (IPC) activities in 
all Detroit-area SNFs. During March 7–May 8, among 2,773 
residents of 26 Detroit SNFs, 1,207 laboratory-confirmed cases 
of COVID-19 were identified during three periods: before 
(March 7–April 7) and after two point prevalence surveys 
(April 8–25 and April 30–May 8): the overall attack rate was 
44%. Within 21 days of receiving their first positive test results, 
446 (37%) of 1,207 COVID-19 patients were hospitalized, 
and 287 (24%) died. Among facilities participating in both 
surveys (n = 12), the percentage of positive test results declined 
from 35% to 18%. Repeated point prevalence surveys in SNFs 
identified asymptomatic COVID-19 cases, informed cohorting 
and IPC practices aimed at reducing transmission, and guided 
prioritization of health department resources for facilities expe-
riencing high levels of SARS-CoV-2 transmission. With the 
increased availability of SARS-CoV-2 testing, repeated point 
prevalence surveys and enhanced and expanded IPC support 
should be standard tools for interrupting and preventing 
COVID-19 outbreaks in SNFs.
From mid-March through early April, rapid increases in con-
firmed COVID-19 cases were detected among SNF residents in 
Detroit. During March 7–April 7, limited SARS-CoV-2 testing 
capacity resulted in prioritization of symptomatic residents for 
testing. Expansion of the Detroit Health Department testing 
capacity in early April enabled testing of Detroit residents from 
all 26 SNFs who had not previously been tested. Any testing 
conducted during April 8–25 was considered part of the first 
point prevalence survey. After the first survey, 12 facilities were 
prioritized for a second survey, in which participation was 
determined by the proportion of positive results from the first 
survey and the feasibility of conducting repeat on-site testing. 
The second survey occurred on a single date at each facility 
during April 30–May 8.
A Detroit Health Department rapid-testing clinic was estab-
lished on April 2, 2020, using the Abbott ID NOW molecular 
COVID-19 test (4). During the first point prevalence sur-
vey, specimens collected from residents’ anterior nares were 
tested using the point-of-care platform in the Detroit Health 
Department rapid-testing clinic. Because of limited test avail-
ability for this platform, testing of specimens for the second 
survey was performed by an off-site reference laboratory using 
nasopharyngeal specimens and the SARS-CoV-2 real-time 
reverse transcription–polymerase chain reaction (RT-PCR) 
assay. At two facilities, anterior nares specimens for the sec-
ond survey were collected and sent to a different reference 
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laboratory for real-time RT-PCR testing. All specimens were 
collected, transported, and tested in accordance with CDC 
recommendations (5).
On-site IPC assessments and consultation were provided 
to facility leaders in all 26 SNFs during the first survey. Two 
follow-up IPC assessments were conducted for the 12 facilities 
participating in the second survey and included examination 
of cohorting practices using a facility floorplan, supply and 
use of personal protective equipment, hand hygiene practices, 
staffing mitigation planning, and other IPC activities.
Individual-level data on positive test dates, symptom status, 
hospitalizations, and fatalities were collected from Detroit 
Health Department COVID-19 case investigations, laboratory 
requisition forms, cases reported to the Michigan Department 
of Health and Human Services, and a review of death certifi-
cates. Symptom information at the time of testing was collected 
by oral report from facility nurse managers or from docu-
mentation of resident symptom screening. Hospitalizations 
included those with admission dates 2 days before through 
21 days after the collection of a specimen with a positive test 
result for SARS-CoV-2, and deaths included those occurring 
within 21 days of collection of a positive specimen. To iden-
tify ongoing transmission, facility-level percentages of newly 
identified cases (residents with newly diagnosed SARS-CoV-2 
infection divided by total number of residents tested without 
previous positive test results) were compared across facilities 
for each of the survey periods. Data were collected as part of 
public health response activities and were determined by CDC 
not to constitute human subject research.* Persons provided 
consent for testing and symptom screening, consistent with 
the policies of the facility. Analyses were conducted using SAS 
software (version 9.4; SAS Institute). 
During March 7–May 8, among 2,773 Detroit SNF resi-
dents, 1,207 (44%) laboratory-confirmed COVID-19 cases 
were identified (Table). Among residents with positive test 
results, the median patient age was 72 years (interquartile 
range [IQR] = 64–82 years), 446 (37%) were hospitalized, and 
287 (24%) died (Figure), including 233 (52%) hospitalized 
patients. Among 1,027 COVID-19 patients with symptom 
data available, 566 (55%) were symptomatic at the time of their 
first positive test result; this was highest before the first point 
prevalence survey (93%), decreased to 48% in the first survey, 
and decreased further to 4% in the second survey. Among 566 
COVID-19 patients who reported symptoms, 227 (40%) died 
within 21 days of testing, compared with 25 (5%) among 461 
patients who reported no symptoms; 35 (19%) deaths occurred 
among 180 patients for whom symptom status was unknown. 
* https://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&SID=83cd09e1c0f4c6937c
d9d7413160fc3f&pitd=20180719&n=pt44.1.46&r=PART&ty=HTML.
Before the first survey, 332 residents had positive SARS-CoV-2 
test results (range = 2–32 per facility). The median interval 
from first documented symptom onset in a facility until the 
first survey was 33 days (range = 20–44 days). The average 
facility census during the time of the first survey (April 8–25) 
was 96 residents (range  =  38–169). During this time, 716 
residents (32%) received a positive SARS-CoV-2 test result 
among 2,218 who had not previously received a positive test 
result; facilities each identified six to 77 residents with newly 
diagnosed infections (range = 7%–58% of residents).
Among the 12 facilities participating in the second point 
prevalence survey during April 30–May 8, eight had imple-
mented cohorting of residents with positive test results in a 
dedicated COVID-19 unit before the first survey; the remain-
ing four facilities initiated cohorting shortly after receiving 
results from the first survey. Four of 12 facilities that took part 
in the second survey did not dedicate health care personnel 
to exclusively care for residents within the COVID-19 unit, 
primarily because of staffing shortages.
The average census of facilities participating in the second 
survey was 80 residents (range = 36–147), and 373 of 1,063 
(35%) residents had received positive test results during the 
first survey. Among 637 residents tested during the second 
survey who were not previously known to have COVID-19, 
18% (115) had positive SARS-CoV-2 test results; including 
17% (85 of 491) of residents whose test results during the 
first survey had been negative. The median interval between 
the first and second surveys was 15 days (IQR = 14–17 days). 
Facilities identified two to 19 new cases during the second 
point prevalence survey (range = 3%–31% of residents tested).
Discussion
Facility-wide testing conducted among residents living in 26 
SNFs in an urban Detroit jurisdiction with high SARS-CoV-2 
prevalence identified an overall attack rate of 44%, a 37% 
COVID-19 hospitalization rate, and a 24% fatality rate 
amid ongoing and widespread SARS-CoV-2 transmission. 
Repeated point prevalence surveys enabled early identifica-
tion of COVID-19 cases (including asymptomatic patients), 
informed cohorting and IPC practices, and guided prioritiza-
tion of health department resources.
Despite barriers to implementing rapid repeated point preva-
lence surveys, this assessment demonstrates benefits of conduct-
ing repeated surveys in SNFs. Among facilities participating in 
both surveys, the percentage of new laboratory-confirmed cases 
declined from 35% to 18%, suggesting that facility-wide testing 
and on-site IPC support might have contributed to reductions in 
SARS-CoV-2 transmission. Following testing and establishment 
of a COVID-19 care unit, IPC assessment and consultation were 
critical to assisting facilities in targeting interventions to mitigate 
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TABLE. Initial and follow-up point prevalence survey test results for Detroit skilled nursing facility residents before the survey period, at the 
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All 2,773 1,207 (44) 446 (37) 287 (24) 332 93 2,218 716 (32) 48 637 115 (18) 4
A 185 91 (49) 35 (38) 20 (22) 31 97 122 39 (32) 38 80 19 (24) 5
B 166 87 (52) 37 (43) 23 (26) 32 97 108 35 (32) 60 75 19 (25) 11
C 137 61 (45) 15 (25) 6 (10) 2 100 115 46 (40) 18 68 12 (18) 0
D 118 24 (20) 18 (75) 11 (46) 16 100 87 6 (7) 83 64 2 (3) 50
E 137 75 (55) 40 (53) 24 (32) 27 100 102 29 (28) 61 59 18 (31) 0
F 97 51 (53) 11 (22) 10 (20) 14 100 76 23 (30) 22 54 13 (24) 8
G 98 31 (32) 5 (16) 3 (10) 3 100 76 20 (26) 100 51 8 (16) 0
H 175 105 (60) 31 (30) 23 (22) 22 95 139 77 (55) 47 48 5 (10) 0
I 100 52 (52) 19 (37) 14 (27) 16 88 66 29 (44) 36 48 5 (10) 0
J 121 68 (56) 18 (26) 14 (21) 26 92 80 35 (44) 41 42 7 (17) 0
K 61 26 (43) 10 (38) 6 (23) 3 100 55 19 (35) 100 29 3 (10) 0
L 51 26 (51) 8 (31) 2 (8) 7 71 37 15 (41) 20 19 4 (21) 0
M 161 34 (21) 20 (59) 14 (41) 10 90 151 24 (16) 47 —§ — —
N 122 36 (30) 9 (25) 9 (25) 7 100 112 27 (24) 100 — — —
O 122 44 (36) 24 (55) 13 (30) 18 83 97 24 (25) 50 — — —
P 109 40 (37) 15 (38) 7 (18) 12 92 88 21 (24) 37 — — —
Q 106 67 (63) 16 (24) 12 (18) 15 67 85 38 (45) 73 — — —
R 100 29 (29) 14 (48) 12 (41) 13 92 86 16 (19) 44 — — —
S 87 32 (37) 16 (50) 11 (34) 16 93 66 15 (23) 36 — — —
T 85 14 (16) 8 (57) 3 (21) 8 Unknown 77 6 (8) Unknown — — —
U 83 55 (66) 18 (33) 12 (22) 14 86 66 38 (58) 89 — — —
V 79 48 (61) 24 (50) 15 (31) 5 100 73 41 (56) 72 — — —
W 80 36 (45) 7 (19) 6 (17) 2 50 77 34 (44) 26 — — —
X 75 26 (35) 13 (50) 4 (15) 4 100 68 19 (28) 42 — — —
Y 64 34 (53) 10 (29) 7 (21) 3 100 61 31 (51) 13 — — —
Z 54 15 (28) 5 (31) 6 (38) 6 100 48 9 (19) 50 — — —
* Hospitalizations with admission dates documented as 2 days before, through 21 days after, the specimen collection date for a positive SARS-CoV-2 test result were 
counted; deaths within 21 days of positive specimen collection date were counted. Missing dates were considered to be within 21 days of specimen collection.
† Total tested refers to residents tested at any time through May 8, 2020. Tested refers to residents tested in each period who were not previously known to have 
SARS-CoV-2 infection. 
§ Dashes indicate that facilities did not participate in the follow-up survey. 
suspected causes of ongoing transmission. These included 
incomplete resident and health care personnel cohorting, contin-
ued reintroduction of the virus (e.g., from admission of residents 
with unknown COVID-19 status or residents requiring routine 
outpatient medical treatment, such as hemodialysis), and space 
limitations prohibiting use of private rooms to isolate residents 
whose infection status was unknown. Repeated point prevalence 
surveys might also improve patient outcomes by enabling earlier 
identification and initiation of clinical patient monitoring (e.g., 
assessing vital signs more frequently) and, when warranted, rapid 
transfer to acute care facilities.
The findings in this report are subject to at least four limi-
tations. First, although asymptomatic health care personnel 
with SARS-CoV-2 infection are a likely source of transmis-
sion, health care personnel were not tested on the same day 
as were residents, and results of health care personnel testing 
were not available for inclusion in this report. Second, the long 
testing interval might influence interpretation of results. The 
first point prevalence survey occurred approximately 1 month 
after SARS-CoV-2 introduction in most facilities; therefore, 
asymptomatic cases identified during the first survey might 
represent residents who recovered from illness but still had 
positive RT-PCR test results. Further, the 14-day interval 
between the two surveys might have resulted in less effective 
case identification than a shorter interval would have. Third, 
testing methods in the two surveys varied, as did test charac-
teristics across different platforms and specimen sources (6). 
Finally, at the time of manuscript drafting, data for repeated 
point prevalence surveys were available for only 12 out of 26 
facilities, which limited our ability to fully describe ongoing 
SARS-CoV-2 transmission among Detroit SNFs.  
When repeated point prevalence surveys are implemented as 
part of COVID-19 response strategies in SNFs, testing results 
should inform prompt and specific actions, such as 1) using 
transmission-based precautions for resident care and exclud-
ing health care personnel with positive test results from work; 
2) strict cohorting of residents and health care personnel; 
3) active clinical monitoring of confirmed COVID-19 cases; 
Early Release
4 MMWR / July 1, 2020 / Vol. 69
FIGURE. Skilled nursing facility residents with confirmed COVID-19 diagnosed by May 8, 2020, (A) by date of first positive SARS-CoV-2 test 
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C. Date of death
B. Hospitalizations, by hospital admission date





Abbreviation: COVID-19 = coronavirus disease 2019.
 * Seventeen dates of first positive test results are not known.
 † Five residents had multiple admissions; 120 had unknown hospitalization dates. 
 § Hospitalization and mortality data were current as of May 29, 2020. Hospitalizations with admission dates documented as 2 days before, through 21 days after the 
specimen collection date for a positive SARS-CoV-2 test were counted; deaths within 21 days of positive specimen collection date were counted.
 ¶ Five dates of death are not known.
 ** Data from all 26 facilities are displayed; only 12 facilities were tested during the second survey. COVID-19 testing data are not shown after May 8. 
4) managing safe transitions of care to and from outside facili-
ties; and 5) discontinuing transmission-based precautions if a 
test-based strategy is used (7,8). In response to a confirmed case, 
CDC now recommends repeat testing (e.g., every 3–7 days) of all 
residents and health care personnel who previously had negative 
test results until testing identifies no new cases of COVID-19 
among residents or health care personnel (9). Widescale testing 
activities should be integrated with intensified IPC support 
from local and state health departments.
Repeated point prevalence surveys coupled with IPC sup-
port might have reduced SARS-CoV-2 transmission in SNFs 
in Detroit and have the potential to improve outcomes among 
SNF residents. New cases continued to be identified during the 
second survey; however, reductions in 21-day hospitalization 
and mortality rates were observed throughout the implemen-
tation period. Future studies of COVID-19 in SNFs should 
further explore the impact of repeated point prevalence surveys 
on morbidity and mortality, the role of asymptomatic health 
care personnel in SARS-CoV-2 transmission, and the role of 
serologic testing in reopening SNFs following outbreaks. As the 
availability of SARS-CoV-2 testing increases, repeated point 
prevalence surveys and intensified IPC support from public 
health practitioners are essential components of COVID-19 
IPC strategies in SNFs experiencing COVID-19 outbreaks.
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Summary
What is already known about this topic?
Symptom-based screening in skilled nursing facilities (SNFs) is 
inadequate to detect SARS-CoV-2 transmission. Repeated 
point prevalence surveys can identify asymptomatic cases 
during outbreaks.
What is added by this report?
Repeated point prevalence surveys at 26 Detroit SNFs identified 
an attack rate of 44%; within 21 days of diagnosis, 37% of 
infected patients were hospitalized and 24% died. Among 12 
facilities participating in a second survey and receiving on-site 
infection prevention and control (IPC) support, the percentage 
of newly identified cases decreased from 35% to 18%.
What are the implications for public health practice?
Repeated point prevalence surveys in SNFs can identify asymp-
tomatic COVID-19 cases, inform cohorting and IPC practices, and 
guide prioritization of health department resources.
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